Schwameis, Michael <br/><br/>
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial.  [electronic resource] 

 -  The Lancet. Infectious diseases  09 2016 
 - 1036-1044 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-4457 
<br/><br/><label>Standard No.: </label>10.1016/S1473-3099(16)30115-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adolescent<br/>Adult<br/>Bacterial Toxins--isolation & purification<br/>Double-Blind Method<br/>Enterotoxins--isolation & purification<br/>Female<br/>Healthy Volunteers<br/>Humans<br/>Immunization Schedule<br/>Immunization, Secondary--methods<br/>Male<br/>Middle Aged<br/>Shock, Septic--prevention & control<br/>Superantigens--isolation & purification<br/>Vaccination<br/>Vaccines, Synthetic--administration & dosage<br/>Young Adult